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ABSTRACT: This paper describes a disposable amperometric biosensor for simple
and sensitive determination of miRNA-21. The bioplatform consists of gold
nanoparticles-nanostructured electrode surfaces on which a direct hybridization
assay involving the immobilization of a specific thiolated DNA capture probe and
recognition of the formed DNA−miRNA-21 heteroduplex by a specific antibody is
implemented. The antibody is further recognized through its Fc region by a
commercial bacterial protein containing 40 units of horseradish peroxidase (HRP)
(ProtA-polyHRP40). The amperometric detection of the hybridization process using
the H2O2/hydroquinone system allows quantification of the target miRNA in the
0.096−25 pM linear range with a detection limit of 29 fM (0.29 amol in 10 μL of
sample). The bioplatform offers excellent selectivity against noncomplementary
sequences and very acceptable against sequences with an unpaired base (only 30% of
the response obtained for the target miRNA). In addition, the bioplatform was
shown to be useful for the determination of the endogenous content of the target
oncomiR directly in blood serum from breast cancer patients and in breast cancer cells using only 10 ng of total extracted RNA.
1. INTRODUCTION
Nanostructured electrodes with gold nanoparticles (AuNPs)
have demonstrated unique properties in the development of
nucleic acid electrochemical biosensors with improved
analytical performances. The catalytic activity of the AuNPs
together with their large surface area and excellent biocompat-
ibility make these nanostructured surfaces more conductive
and allow the immobilization of large probe loadings with
optimal orientation and spacing for efficient hybridization,
keeping their biological activity and storage stability.1−4 The
resulting bioplatforms exhibit also interesting advantages in
terms of simplicity, cost, assay time, and applicability in
different environments. These characteristics make AuNPs-
involved bioplatforms especially attractive compared to
conventional methodologies for their implementation in
routine determinations.
These properties have been successfully harnessed to
develop electrochemical platforms for the determination of
biomarkers of high clinical relevance, such as miRNAs,5,6 a
class of endogenous and small noncoding RNAs that play a
relevant role in many diseases, particularly in human cancers.7,8
Alterations in miRNA expression levels are involved in the
initiation and progression of human cancers, and minimal
signature profiles have been identified for various types of
human cancers, where miRNAs can be regulated both upward
and downward. Therefore, the determination of regulatory
patterns is of great importance since they can provide relevant
information about tumor initiation, invasion, and metastasis
processes.
However, the determination of miRNAs is highly complex
due to their short sequence, low concentration level, and high
sequence similarity between members of the same family.
Conventional available methods for miRNAs determination,
such as northern blotting,9,10 in situ hybridization, reverse
transcription polymerase chain reaction,11−13 and miRNA
microarrays,14−17 suffer from important limitations (use in
centralized laboratories, expensive, laborious, require speci-
alized personnel, and poorly portable instrumentation), which
make the development of more simple and rapid alternative
strategies highly desirable.
In recent years, several electrochemical platforms have been
reported for the single or simultaneous determination of
miRNAs either using integrated formats4,18−22 or involving
magnetic beads (MBs).23−27 However, many of these
biosensors require amplification strategies, which demand
complex and/or long protocols to achieve the required
sensitivity. This is an important restriction for their wide use
in clinical practice by unskilled personnel. In this context,
particularly attractive and relatively simple electrochemical
strategies have been reported recently with acceptable
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sensitivity using commercial capture and detector bioreceptors
with high affinity toward RNA homohybrids (viral protein
p194,28−31) and heterohybrids (anti-DNA−RNA hybrid anti-
bodies19−21,23,25,26).
This paper describes a novel electrochemical bioplatform for
miRNAs determination, which combines the simplicity of a
direct DNA−RNA hybridization format with the advantages of
disposable AuNPs-nanostructured platforms and the high
specificity and affinity of anti-DNA−RNA hybrid antibodies.
To achieve high sensitivity, an easily implementable
amplification strategy using a multienzyme bacterial protein
able to recognize the Fc region of the anti-DNA−RNA hybrid
antibody is used. The hybridization reaction is monitored
amperometrically with the H2O2/hydroquinone (HQ) system.
The resulting biosensor exhibits interesting performance in
terms of sensitivity, selectivity, and reduced fabrication and
assay times. It was successfully applied for the reliable and
accurate determination of the selected target miRNA-21 (a
relevant onco-miRNA32) directly in a five-times diluted human
blood serum from breast cancer patients as well as in breast
cancer cells using the lowest amount of total extracted RNA
reported to date for an electrochemical biosensor.
2. RESULTS AND DISCUSSION
The developed strategy is displayed in Scheme 1. It involves
direct RNA−DNA hybridization implemented on disposable
carbon surfaces nanostructured with AuNPs. The target
miRNA was selectively captured on the nanostructured
surfaces by efficient hybridization with a complementary
thiolated DNA probe. The resulting heterohybrid was
recognized with an antibody with high affinity for these
heteroduplexes, which was labeled with a bacterial binding
antibody protein (ProtA) conjugated with a homopolymer
containing 40 horseradish peroxidase (HRP) units. The extent
of the hybridization reaction and thus of the miRNA-21
concentration was monitored by amperometry in the presence
of the H2O2/HQ system. Interestingly, both the nano-
structured disposable surfaces and all necessary reagents
involved in this strategy are commercially available.
Scheme 1. Schematic Display of the Biosensor Developed with AuNPs/Screen-Printed Carbon Based Electrodes (SPCEs) for
the Amperometric Determination of miRNA-21 Involving a Specific HS-DNA Probe, Direct DNA/miRNA Hybridization, And
the Use of Anti-DNA−RNA Antibody As Detection Bioreceptor Further Labeled with ProtA-PolyHRP40
a.
Figure 1. Amperometric responses obtained in the absence and presence of 20 pM synthetic miRNA-21 at AuNPs/SPCEs with and without
immobilized HS-DNA probe (a) and in the presence of 20 pM miRNA-21 at AuNPs/SPCEs modified with HS-DNA or HS-RNA probes
complementary to miRNA-21 (b).
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Figure 1 shows the comparison of the amperometric traces
recorded in the absence and presence of the target miRNA at
unmodified AuNPs/SPCEs and modified with HS-DNA and
HS-RNA capture probes. Negligible and similar amperometric
responses were observed in the absence of miRNA-21 on HS-
DNA/AuNPs/SPCEs and in the presence of 20 pM miRNA-
21 on AuNPs/SPCEs with no immobilized HS-DNA capture
probe immobilized and on complementary HS-RNA/AuNPs/
SPCEs (Figure 1b). These results confirmed that the
amperometric responses were due to the efficient hybridization
of the HS-DNA capture probe with the target miRNA, the
negligible nonspecific adsorption of anti-DNA−RNA hybrid
antibody and ProtA-polyHRP40 on the AuNPs/SPCEs
surface, and the specificity of the antibody for the selective
detection of DNA−RNA heterohybrids.33−35
2.1. Optimization of the Experimental Variables. The
most relevant experimental variables affecting the behavior of
the designed bioelectrode were optimized. The current
measured in the presence of 20 pM (signal, S) and in the
absence (noise, N) of the target miRNA-21 as well as the
corresponding ratio (S/N ratio) were used as selection criteria.
The results obtained are shown in Figure 2 and summarized in
Table 1. Apart from these, other variables used involved in the
modification of AuNPs/SPCE, such as the HS-DNA probe
concentration, the hybridization time with the target
miRNA,4,22 the pH value, the detection potential, and the
concentrations of H2O2 and HQ, were taken from previous
works.36−38
Figure 2a,b shows the effect of the concentration of
bioreagents used to carry out the heterohybrid recognition
and the enzymatic labeling on the biosensor response. The 1/
1000 and 1/50 dilutions of the anti-DNA−RNA hybrid
antibody and ProtA-polyHRP40 conjugate provided larger S/
N ratios, and therefore, they were selected for further work.
In an attempt to simplify the whole working protocol and
reduce the assay time, the influence of the number of steps
involved in the preparation of the biosensor on its analytical
behavior was checked; 30 min incubation steps were assayed in
all cases starting from the preparation of HS-DNA/AuNPs/
SPCEs. Figure 2c shows a comparison between the results
obtained with the following working protocols:
Figure 2. Dependence of the amperometric signals measured at HS-DNA/AuNPs/SPCEs in the absence (N) and presence of 20 pM miRNA-21
(S) on the corresponding S/N ratio with the anti-DNA−RNA antibody (a) and the ProtA-polyHRP40 (b) concentration on the steps number used
for the preparation of the biosensor (c) and the incubation time with the mixture solution containing the DNA−RNA hybrid antibody and ProtA-
polyHRP40 (d). The error bars are estimated as triple of the standard deviation (SD) of three replicates.
Table 1. Evaluation of Different Experimental Variables
Involved in the Preparation and Functioning of the
Developed Biosensor
variable evaluated range
optimal
value
selected
anti-DNA−RNA hybrid antibody (dilution) 1/5000−1/250 1/1000
ProtA-polyHRP40 (dilution) 1/500−1/5 1/50
incubation time with mixture DNA−RNA
hybrid antibody + ProtA-polyHRP40
(min)
0−90 60
number of stepsa 1−3 2
aStarting from the preparation of HS-DNA/AuNPs/SPCEs.
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• One single incubation step with a mixture solution
consisting of the target miRNA, anti-DNA−RNA
antibody, and ProtA-polyHRP40.
• Two successive incubation steps: first with the target
miRNA and thereafter with a mixture solution
containing anti-DNA−RNA antibody and ProtA-pol-
yHRP40.
• Three successive incubation steps with the target
miRNA, anti-DNA−RNA antibody, and ProtA-pol-
yHRP40.
Figure 2c shows clearly that the protocol involving two
successive incubation steps provided a larger S/N current ratio.
These results suggest that the mixing of all of the bioreagents
worsened the efficiency of the hybridization process, whereas
the anti-DNA−RNA antibody was better recognized by ProtA-
polyHRP40 when both reagents were incubated in homoge-
neous solution. Once the optimal working protocol was
selected, the influence of the incubation time with the mixture
of anti-DNA−RNA antibody and ProtA-polyHRP40 to label
the DNA/miRNA heteroduplex captured on the electrode was
evaluated. As it is shown in Figure 2d, there were no significant
differences for the nonspecific responses, but the specific
current increased notably with the incubation time up to 60
min. Accordingly, this incubation time ensured an efficient
labeling of the immobilized heterohybrids and was selected for
further studies.
2.2. Analytical Characteristics. Figure 3 shows the
amperometric responses obtained for different concentrations
of the synthetic target miRNA as well as the corresponding
calibration plot. As expected for a direct hybridization assay,
the Δi values (measured as described in Section 4.5) increased
linearly (correlation factor r: 0.998) with the miRNA-21
concentration from 0.096 to 25 pM, with a slope value of 378
± 7 nA pM−1. The limit of detection (LOD), defined as the
concentration of the analyte that gives a signal that is
significantly different from the blank, was estimated from the
signal of the blank plus 3 times the standard deviation of the
signal values for 10 independent amperometric measurements
obtained without target miRNA. The resulting LOD was 29
fM (0.29 amol in 10 μL sample).
A comparison of the analytical performance of the developed
biosensor with that of other electrochemical biosensors
reported for the determination of miRNAs using also DNA−
RNA heterohybrid-specific antibodies is shown in Table 2. The
LOD value provided by the developed biosensor is notably
better than that achieved with biosensors involving the use of
magnetic microbeads23,26 and similar to that claimed using
electrodes nanostructured with carbon nanomaterials.19,20
Importantly, no application is reported for this latter approach.
The achieved LOD is also higher than that given for the sensor
using AuNP-modified glassy carbon electrode (GCE) and
applied for the determination in RNAt extracted from rice
seedlings.21 However, both the fabrication and assay time of
the developed sensor are remarkably shorter than those
required using these more sensitive strategies (Table 2).
Interestingly, the designed bioscaffold provides about 7-
times enhanced sensitivity (55.3 vs 378 nA pM) and a 34-times
lower LOD value (0.29 vs 10 amol) than the performance
exhibited by a magnetic microbeads-based biosensor involving
the same bioreagents.26 The improved performance can be
attributed to the inherent conductivity and catalytic activity of
AuNPs and the enhanced immobilization of nucleic acid probe
with an adequate orientation and spacing to improve the target
accessibility at the nanostructured surfaces.1−4 Indeed, the
LOD achieved with this biosensor is rather similar to the
values claimed for other biosensors reported recently for the
amperometric determination of miRNAs at AuNPs/SPCEs
using competitive and direct RNA/RNA hybridization assays
using Strep-HRP and the viral protein p19, respectively.4−22
Importantly, as shown below, the sensitivity achieved is
sufficient to allow quantification using a significantly small
amount of extracted RNAt. Moreover, the higher stability of
DNA probes compared to RNA probes can be considered as
another relevant practical advantage of the developed method-
ology.39
The reproducibility of the measurements carried out with
the developed bioplatform was checked by comparing the
currents obtained for 1 pM miRNA-21 with nine different
biosensors prepared in the same manner. A relative standard
deviation value of 2.9% was calculated to show an excellent
reproducibility in both the biosensor preparation and
amperometric measurement procedures.
Regarding the storage stability of the bioplatforms, the
currents measured with HS-DNA/AuNPs/SPCEs, which were
stored at 4 °C in a humidified chamber (after incubation with
1% (w/v) bovine serum albumin (BSA)), for 0 and 1.0 pM
miRNA-21 showed that they remained within the set control
limits over a 2 month period (no longer times were tested)
(Figure 4). This attractive storage stability, in good agreement
with the behavior observed for bioelectrodes involving
thiolated RNA probes at disposable AuNP-nanostructured
scaffolds,4,22 is attributed to the great biocompatibility and
major role played by AuNPs in keeping the activity of the
biomolecules immobilized onto their surface.
2.3. Selectivity. Due to the high sequence homology
between miRNA family members, a very important feature of
miRNAs biosensing platforms is the selectivity toward other
nontarget and mismatched miRNA sequences. Figure 5
displays amperometric traces provided by the HS-DNA/
AuNPs/SPCEs in the absence and presence of the synthetic
target miRNA, a single-central base mismatched (1-m) and a
Figure 3. Amperometric traces obtained with the resulting HS-DNA/
AuNPs/SPCE biosensors for different concentrations of the synthetic
target miRNA-21. Inset: calibration plot. The error bars are estimated
as triple of the standard deviation of three replicates.
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fully noncomplementary miRNA (miRNA-451). A very small
response similar to that measured without target miRNA was
obtained for the noncomplementary sequence. The 1-m
sequence provided a 30% response of that obtained for the
target miRNA. These findings are of particular interest for the
applicability of the method in challenging samples, such as raw
cellular RNAt, where the target miRNA is present with many
other nontarget miRNAs. The selectivity achieved toward 1-m
sequences (30% hybridization efficiency assigning 100% for the
target miRNA) is better than that demonstrated for other
electrochemical biosensors using anti-RNA−DNA hybrid
antibodies (4826 and 51%23) requiring similar assay times,
while it is slightly worse (30 vs 14%) than that claimed for the
strategy requiring an assay time 3 times longer.21
2.4. Determination of the Endogenous Content of
miRNA-21 in Serum from Breast Cancer Patients and
RNAt Extracted from Breast Cancer Cells. The practicalT
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Figure 4. Storage stability of HS-DNA/AuNPs/SPCEs at 4 °C in a
humidified chamber. Amperometric signals provided by biosensors
prepared with the bioplatforms stored at different times in the absence
and presence of 1 pM synthetic miRNA-21. Control limits were set at
±3 × SD of the mean current values measured with five different
sensors prepared on the first day of the study.
Figure 5. Amperometric traces recorded with HS-DNA/AuNPs/
SPCEs in the absence of the target miRNA and in the presence of 20
pM miRNA-21, 1-m and noncomplementary (miRNA-451) sequen-
ces.
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suitability of the developed methodology was tested by
determining the endogenous content of miRNA-21 directly
in blood serum from breast cancer patients and in raw RNAt
extracted from breast cancer cells.
Figure 6a shows the amperometric traces recorded with the
developed biosensors for the three serum samples analyzed
(one from a healthy individual and two from patients
diagnosed with breast cancer). The samples were five-times
diluted and heated, as described in Section 4.6. These results
are in agreement with those reported by other authors40
showing that miRNA-21 expression is about 3−4 times larger
in breast cancer patients that in healthy individuals using an
indirect highly liquid chromatography−mass spectrometry
(MS)/MS method.41 No significant differences were found
for the slope values of the calibration plot constructed with
miRNA-21 standards (Figure 3, 378 ± 7 nA pM−1) and of the
calibration graphs constructed for five-times diluted and heated
sera from the healthy individual (374 ± 8 nA pM−1) and the
breast cancer patients 353 ± 8 nA pM−1 spiked with growing
amounts of synthetic miRNA-21 up to 20 pM. This made the
determination of the endogenous concentration of the target
miRNA in serum feasible by simple interpolation of the Δi
values measured for the diluted samples into the miRNA
standards calibration plot. The concentrations of miRNA-21
obtained were 2.0 ± 0.2, 8.0 ± 0.3, and 7.3 ± 0.4 pM in the
serum samples from the healthy individual and breast cancer
patients 1 and 2, respectively.
Regarding the determination of miRNA-21 in cellular
extracted RNAt, Figure 6b shows the amperometric traces
provided by the HS-DNA/AuNPs/SPCEs showing the
expected miRNA-21 3−4 times higher expression in the
tumorigenic (MCF-7) compared to the nontumorigenic
(MCF-10A) cells according to the oncogenic role of this
miRNA.41,42 Similar to that observed in diluted and heated
serum samples, no statistically significant differences were
found between the slope values of the corresponding
calibration plots constructed with the synthetic target
miRNA-21 both in buffered solutions and in the presence of
10 ng of RNAt extracted from MCF-10A cells 354 ± 9 nA
pM−1, thus confirming the absence of apparent matrix effect in
the cellular RNAt analysis. Interpolation in the miRNA-21
standard calibration plot provided concentrations of 0.82 ±
1.05 and 2.97 ± 3.22 amol ng−1 RNAt in MCF-10A and MCF-
7 cells, respectively. These results are in complete agreement
with those reported previously with concentrations ranging
from 0.8 to 1.0 amol ng−1 RNAt in MCF-10A and from 2.3 to
3.3 amol ng−1 RNAt in MCF-7 cells.
4,23,43,26 These results
demonstrate the bioplatform usefulness for the accurate and
selective determination of the target miRNA in the presence of
many other nontarget miRNAs. Importantly, this determi-
nation can be accomplished using the lowest amount of raw
RNAt reported so far with electrochemical biosen-
sors,4,24,26,27,29,30,44 which required between 50 and 1000 ng
of RNAt extracted from cells to perform the target miRNA
determination.
3. CONCLUSIONS
This work reports a novel amperometric bioplatform to
determine miRNA-21. Combining the inherent advantages of
disposable surfaces nanostructured with gold nanoparticles
with the use of selective antibodies to DNA−RNA
heteroduplexes and bacterial immunoglobulin-binding protein
conjugated to multiple HRP units made this determination
possible with an LOD as low as 29 fM and good discrimination
toward sequences with a single unpaired base. Interestingly,
this bioplatform is able to accurately determine the
endogenous content of miRNA-21 directly in human blood
serum from breast cancer patients and in breast cancer cells
using very small amount of RNAt. It should be emphasized that
no target miRNA amplification steps are required with this
strategy. In addition, all of the reagents and disposable
electrodes used are commercially available, making this
bioscaffold particularly attractive to be handled by non-
specialized personnel and even on an outpatient basis for
routine determinations.
4. EXPERIMENTAL SECTION
4.1. Apparatus and Electrodes. Amperometric measure-
ments were performed with a Metrohm Autolab PGSTAT
M204 electrochemical workstation using Nova v1.11 software.
The transducers, purchased from Dropsens S.L. (Oviedo,
Spain), were AuNP-modified screen-printed carbon electrodes
(ref DRP-110GNP) consisting of a 4 mm diameter working
electrode, a carbon counter electrode, and a Ag pseudorefer-
ence electrode and the specific cable connector with the
potentiostat (ref DRP-CAC). Scanning electron microscopy
(SEM) characterization studies carried out both by us and by
the electrode supplier company confirm the presence of
Figure 6. Amperometric responses measured with HS-DNA/AuNPs/SPCEs in the absence of the target miRNA and for five-times diluted and
heated serum samples (a) or 10 ng raw RNAt extracted from breast cells (b).
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AuNPs homogeneously distributed over the whole surface with
a mean diameter of 30 nm.
A Bunsen AGT-9 Vortex, a Raypa steam sterilizer, a Telstar
Biostar biological safety cabinet, an Optic Ivymen System
incubator shaker (Comecta S.A., Sharlab), and a NanoDrop
ND-1000 spectrophotometer were employed.
4.2. Reagents and Solutions. Highest available grade
reagents were used. NaH2PO4, Na2HPO4, NaCl, and KCl were
purchased from Scharlab. Tris-(hydroxymethyl)aminomethane
hydrochloride (Tris−HCl), mercaptohexanol (MCH), hydro-
quinone, H2O2 (30%, w/v), ethylenediaminetetraacetic acid
(EDTA), and bovine serum albumin (BSA) were purchased
from Sigma-Aldrich (Germany).
ProtA-polyHRP40, a native ProtA labeled with a homopol-
ymer containing 40 HRP molecules (antibodies-online), and
an anti-DNA−RNA hybrid antibody (AbS9.6) from Kerafast
(Boston, MA) were commercially available. A commercial
blocker solution, consisting of a phosphate-buffered saline
(PBS) containing 1% w/v purified casein, from Thermo
Scientific (Waltham, MA) was also used.
The buffer solutions were prepared with Milli-Q water (18
MΩ cm at 25 °C) and sterilized after their preparation to avoid
RNase degradation. Phosphate-buffered saline (PBS) consisted
of 0.01 M phosphate-buffered solution containing 137 mM
NaCl and 2.7 mM KCl (pH 7.5), Tris−EDTA buffer (pH 8.0)
formed by mixing 10 mM Tris−HCl, 1 mM EDTA, and 0.3 M
NaCl (pH 8.0), and phosphate buffer (0.05 M, pH 6.0) were
used.
The synthetic oligonucleotides used (sequences shown in
Table 3) were purchased from Sigma-Aldrich (Germany).
Once received, they were reconstituted in nuclease-free water
to give a final concentration of 100 μM and stored at −80 °C
divided into small aliquots.
4.3. Preparation of HS-DNA/AuNPs/SPCEs. Immobili-
zation of HS-DNA onto AuNPs/SPCEs was carried out
following the protocol described in our previous works.4,22
Briefly, a 10 μL aliquot of a 0.05 μM DNA capture probe
solution was incubated over the working electrode in a
humidified chamber (8 h, 4 °C). After washing thoroughly
with water and drying with nitrogen, the HS-DNA/AuNPs/
SPCEs was treated with 10 μL of 0.1 mM MCH and 1% (w/v)
BSA solutions (both prepared in Tris−EDTA, pH 8.0) for 5
min and 1 h, respectively.
4.4. Hybridization with the Target miRNA and
Labeling of the DNA/RNA Heteroduplex with Anti-
RNA−DNA Antibodies and ProtA-PolyHRP40. A 10 μL
aliquot of the synthetic target miRNA or the sample (heated
and diluted serum or RNAt extracted from cells, all in sterilized
PBS, pH 7.5) solution was incubated onto the HS-DNA/
AuNPs/SPCEs at room temperature for 30 min to hybridize
the target miRNA with the immobilized DNA probe.
Thereafter, electrodes rinsed with sterilized water and dried
with nitrogen were 60 min incubated with 10 μL of a mixture
solution containing anti-RNA−DNA hybrid antibody and
ProtA-polyHRP40, 1/500 and 1/25 diluted, respectively. This
mixture solution, prepared in blocker casein solution, was
preincubated for 30 min in an incubator shaker (30 °C, 950
rpm). The modified bioelectrodes were rinsed with sterilized
water and dried with nitrogen. To prevent miRNA degradation
by RNases, all manipulations, except the amperometric
measurements, were made in a laminar flow cabinet.
4.5. Amperometric Detection. Amperometric detection
at an applied potential of −0.20 V versus Ag pseudoreference
electrode was carried out in stirred solutions by immersing the
prepared bioelectrodes into an electrochemical cell containing
10 mL of 0.05 M phosphate buffer (pH 6.0) and freshly
prepared 1.0 mM HQ. Once the background current was
stabilized, 50 μL of a 0.1 M H2O2 solution was added and the
current was recorded for about 100 s until reaching the steady-
state current. The Δi values given corresponded to the
difference between the currents measured in the presence and
absence of the target miRNA and are the average of three
replicates (α = 0.05).
4.6. Application for the Analysis of Serum and Breast
Cells-Extracted RNAt. The developed bioplatform was used
for the determination of the endogenous miRNA-21 content
directly in human serum samples (without previous RNAt
extraction) and in RNAt extracted from epithelial non-
tumorigenic and tumorigenic breast cells. Blood serum samples
were provided by Prof. Besma Loueslati (Department of
Biology, University of Tunis El Manar) and collected from
informed consenting patients according to ethical guidelines.
Serum samples corresponded to healthy individuals and breast
cancer patients. A serum aliquot was five-times diluted with the
sterilized PBS (pH 7.5) solution and heated for 15 min at 95
°C (in a Stuart block heater) to release the miRNAs from
microparticles and exosomes.18 Subsequently, a 10 μL aliquot
of the diluted and heated sample was cast onto HS-DNA/
AuNPs/SPCEs and the protocol described in Section 4.4 for
the synthetic target miRNA was followed.
Cell culture and RNAt extraction were performed following
protocols described previously.29,30 The quality and concen-
tration of the extracted RNAt were confirmed by measuring the
absorbance at appropriate wavelengths.
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